Many may recall that in early April, I released a paper I did here on Eye on FDA called “FDA Communications Oversight in a Digital Era” that examined the patterns of enforcement by FDA’s Office of Prescription Drug Promotion as expressed through warning and untitled letters during the years 2008-2012 assessing what differences may exist between traditional communications vehicles and digital properties.
The paper is based on a data base that I have compiled that characterizes warning and untitled letters from 2004 onward. The years 2008-2012 were chosen to reflect a period of time when there was an increasing use of the Internet by people seeking healthcare information and by the ascendancy of social media platforms.
YOU’VE READ THE BOOK! NOW SEE THE MOVIE!
Well, not quite a movie. On Tuesday, May 21 at 12 P.M. Easter Time, I will be conducting a Webinar that overviews the findings from the White Paper and will provide some expanded comparisons of digital and social media, as well as a few other observations from the data base. The Webinar is free and if you would like to register, you can do so here.
The data base allows a vast number of analyses having tracked multiple fields of characteristics including whether a communications vehicle was digital, what type of label the product had (boxed warning or not), the type of violations, the treatment area for the product involved and many more.
I hope you will join me on May 21.
